Buying Intercept Pharmaceuticals Ahead Of The Upcoming Catalysts (Increasing First PT To $175).

ICPT

We picked Intercept Pharmaceuticals (ICPT) in our model portfolio in February this year and predicted that the company may seek accelerated approval in this indication based on interim data. This was when clinicaltrials.gov showed the estimated completion date of the REGENERATE trial in 2021. The...

We picked Intercept Pharmaceuticals (ICPT) in our model portfolio in February this year and predicted that the company may seek accelerated approval in this indication based on interim data. This was when clinicaltrials.gov showed the estimated completion date of the REGENERATE trial in 2021. The...

This article is only available to subscribers of Vasuda Healthcare Analytics
Learn more about Vasuda Healthcare Analytics